4XC1 Stock Overview
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
KalVista Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.70 |
| 52 Week High | US$20.20 |
| 52 Week Low | US$6.90 |
| Beta | 0.91 |
| 1 Month Change | 0% |
| 3 Month Change | -4.46% |
| 1 Year Change | 45.58% |
| 3 Year Change | -46.23% |
| 5 Year Change | -49.92% |
| Change since IPO | 32.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4XC1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.8% | -4.9% | -1.5% |
| 1Y | 45.6% | -19.9% | 0.9% |
Return vs Industry: 4XC1 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 4XC1 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 4XC1 volatility | |
|---|---|
| 4XC1 Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4XC1's share price has been volatile over the past 3 months.
Volatility Over Time: 4XC1's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 118 | Ben Palleiko | www.kalvista.com |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE.
KalVista Pharmaceuticals, Inc. Fundamentals Summary
| 4XC1 fundamental statistics | |
|---|---|
| Market cap | €461.76m |
| Earnings (TTM) | -€101.75m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs 4XC1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4XC1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$84.87m |
| Gross Profit | -US$84.87m |
| Other Expenses | US$23.43m |
| Earnings | -US$108.30m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4XC1 perform over the long term?
See historical performance and comparison